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High-throughput microarrays are being used in expression profiling analyses with the objecties of gene and pathway discovery,
functional characterization of genes, and tumor subclassification. This review summarizes bladder cancer studies dealing with both in
vitro models and clinical specimens, using distinct microarray platforms for target discovery.
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AQMicroarrays constitute a group of technologies characterised by
the common availability of measuring hundreds or thousands of
items, including DNA sequences, RNA transcripts or proteins,
within a single experiment using miniaturised devices. The
appropriate experimental design and the use of well-characterised
in vitro, in vivo systems, as well as well-annotated clinical
specimens allow detailed analysis of biological and clinical
phenotypes. Thus, array technologies represent high-throughput
means to identify molecular targets associated with these biological
and clinical phenotypes by comparing samples representative of
distinct disease states.
Hybridisation-based methods and the microarray format con-
stitute together an extremely versatile platform provide for both
static and dynamic views of DNA structure, as well as RNA and
protein expression patterns in cultured cancer cells and tumour
tissues. The most widespread use of this technology to date has
been the analysis of gene expression (Duggan et al, 1999; Lipshutz
et al, 1999). There is an increasingly broad range of additional
applications for microarrays, including genotyping polymorph-
isms and mutations (Hacia and Collins, 1999; Fan et al, 2000),
determining the sites of DNA-binding proteins (Iyer et al, 2001),
and identifying structural alterations using arrayed comparative
genome hybridisation (CGH) (Pinkel et al, 1998). Similar to other
tumours (De Risi et al, 1996; Golub et al, 1999; Sorlie et al, 2001;
van ’t Veer et al, 2002), it is expected that the histopathological
diagnosis of bladder cancer will be complemented by these
comprehensive procedures. It is also expected that such studies
will generate further insights regarding optimal treatments, based
on the individual molecular signatures of patients affected by
bladder cancer.
The development and implementation of high-throughput array
technologies to primary human tumours is changing the scientific
and clinical paradigm, providing novel predictive and therapeutic
targets for the cancer patient. The challenge now resides in
integrating the anatomic, mostly descriptive knowledge of
neoplastic disease processes, with cellular and molecular biology,
as well as genetics. To the simplicity of the study of a single
molecular marker, we may be able to integrate the complexity of
multiple biological determinants, participating in signalling path-
ways and biological networks. Observational measurements will
become quantified, and these values may guide predictive
nomograms for appropriate intervention. Comprehensive infor-
mation may, in turn, modify empirical clinical treatments for
mechanism-based therapies, aimed at individualised approaches
for the cancer patient.
These technologies represent optimal tools for target identifica-
tion at initiation and critical steps along bladder cancer progres-
sion. Focus should be directed towards the elucidation of the
molecular pathways involved in bladder tumorigenesis, and
progression into invasive and metastatic disease. Further research
is also warranted to characterise the phenomena of squamous
metaplasia and squamous carcinoma of the bladder, as well as
squamous differentiation in the background of transitional cell
carcinoma. The analysis of clinical specimens is expected to
provide expression patterns that may allow to identify which
patients would respond to intravesical or systemic treatments, or
present a higher progression risk to develop invasive or metastatic
disease. These studies will result in individualised bladder cancer
targeted therapies and development of biomarkers of diagnostic
and predictive value for patients with bladder cancer.
MOLECULAR TARGET IDENTIFICATION IN BLAD-
DER CANCER USING EXPRESSION PROFILING WITH
DNA MICROARRAYS
The main challenge in studies using high-throughput techno-
logies resides in making efficient and maximal use of the
generated information (Figure 1). The amount and complexity
of data require multiple computational genomic approaches,
including bioinformatic and biostatistical analyses. Molecular
relationships need to be established with normal and distinct
diseased states. In order to bring this knowledge into clinical
settings, it will be critical to validate the relevant molecular
determinants, and to include them as part of the ongoing clinical
trials. Microarray-based gene expression profiling to the study of
bladder cancer can be divided into those analyzing in vitro
systems, and those centering on clinical material, with the
objectives of achieving gene and pathway discovery, functional
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MOLECULAR STUDIES AIMED AT GENE AND
PATHWAY DISCOVERY
These analyses are mainly based on functional association of
changes in gene expression between different cell states or
phenotypes. This use of associating a change in the expression
of a gene with a change in physiological state is one the simplest
ways in which gene expression profiling can be used to suggest or
predict gene function. Alternatively, expression profiling can be
used for the functional classification of genes, as it is often referred
to as ’guilt by association’. This method is based on the
observation that genes with related expression patterns, genes
that presumably are coregulated, are likely to be functionally
related and involved in the same biological processes or
physiological pathways. When genes with similar expression
profiles are grouped, a process referred to as clustering, novel
genes (usually ESTs) are often found mixed with genes of known
function.
MOLECULAR STUDIES AIMED AT FUNCTIONAL
CLASSIFICATION OF GENES
This represents the traditional approach of assigning a functional
role to a gene when overexpressed, and observing the effect(s) of
its expression on known pathways or processes. Such an approach
has been especially useful in identifying the downstream targets of
transcription factors. The genes identified as either up- or
downregulated in these experiments are likely to play important
roles in the signalling network in which the gene under
investigation participates.
MOLECULAR STUDIES AIMED AT TUMOUR
SUBCLASSIFICATION
This is one of the most promising and powerful applications of
expression profiling with expression microarrays. The integration
of gene expression patterns is providing complementary tools to
histopathological criteria for classifying tumours into biologically
meaningful and clinically useful categories. In addition, expression
profiling of well-annotated tumour specimens has the potential of
identifying target genes for novel diagnostic, prognostic or
therapeutic approaches. High-throughput transcriptome analysis
will become a means at improving cancer treatment by an early
and accurate diagnosis of tumour subtype and determining the
most effective therapeutic intervention.
BLADDER CANCER STUDIES USING IN VITRO
MODELS
Expression profiling using bladder cancer cell lines has been used
to gain insight into the molecular events associated with clinical
disease states, assigning potential functional roles to novel genes in
both tumorigenic and tumour progression processes. The follow-
ing study represents an example of how the technology can be
applied to gene and pathway discovery in bladder cancer. Tumour
cell growth inhibition mediated by genistein was produced to the
susceptible bladder tumour line TCCSUP. Expression profiling was
then analysed at various time points, using cDNA chips. Induction
of genes involved in cell growth and cell cycle, such as EGR-1, was
observed, and these events were related to the proliferation and
differentiation effects of treatment (Chen et al, 2001). The gene
induction in T24 invasive bladder cancer cells exposed to 5-aza-20-
deoxycytidine has also been monitored by expression profiling
studies using oligonucleotide microarrays (Liang et al, 2002). This
analysis revealed the relevance of interferon gamma signaling in
the effects of this methylation inhibitor treatment.
An example of the functional classification of genes applied to
bladder cancer is the study comparing the expression patterns of
p53-mediated apoptosis in resistant tumour cell lines vs sensitive
tumour cell lines using cDNA arrays. The ECV-304 bladder
carcinoma cell line was selected for resistance to p53 by repeated
infections with a p53 recombinant adenovirus Ad5CMV-p53. A
number of potential p53 transcription or related targets were
identified, playing roles in cell cycle regulation, DNA repair, redox
control, cell adhesion, apoptosis, and differentiation. Proline
oxidase, a mitochondrial enzyme involved in the proline/pyrro-
line-5-carboxylate redox cycle, was identified upregulated in
sensitive cells, but not in resistant ones. Further experiments
showed the implication of proline oxidase and the proline/P5C
pathway in p53-induced growth suppression and apoptosis
(Maxwell and Davies, 2000). The expression patterns of a
metastatic variant cell line, the so-called T24T, and the invasive
bladder cancer cell line T24 have been studied using oligonucleo-
tide microarrays. The functional significance of the genetic
differences of these cell lines can be assessed by means of
positional expression profiling methods that compare the expres-
sion data generated by oligonucleotide microarrays based upon
chromosomal position (Harding et al, 2002). The combined use of
spectral karyotyping (SKY) and CGH and expression profiles of
these cells provided high correlation for certain chromosomes
such as 8, 12 and X. This multimodal approach allowed the
validation of candidate genes involved in bladder progression,
such as RhoGDI2 (chromosome 12) at the genetic level (Harding
et al, 2002).
Tumour subtypes classification of bladder cancer cell lines can
also be achieved by means of gene expression analyses. The
expression profiling of nine bladder cancer cell lines have been
compared against a pool containing equal RNA quantities of each
of them using cDNA arrays (Sanchez-Carbayo et al, 2002).
Hierarchical clustering classified these tumour cells according to
the histopathological characteristics of the tumours they were
derived from. Caveolin-1 and keratin 10 were differentially
expressed in a squamous carcinoma cell line and certain invasive
Figure 1 General scheme of the procedure used in tumour expression
profiling for target identification and validation. RNA isolation from cell
lines, tumour biopsy, and control samples is followed by labeling of the
probe, hybridisation with the DNA microarray, data acquisition, and
analysis. Verification of the results can be performed using different
approaches, such as tissue microarray analysis.
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superficial bladder tumour. Interestingly, the expression of these
genes in primary bladder tumours spotted on tissue microarrays
was significantly associated with squamous differentiation, histo-
pathological stage, and tumour grade. Additionally, when a
bootstrapping resampling technique was applied on hierarchical
clustering, the cells clustered based on their p53, RB, and INK4A
status. E-cadherin, zyxin and moesin were identified as genes
differentially expressed in these clusters. It is noteworthy that the
expression of these genes was significantly associated with
histopathological stage and tumour grade as well. These results
revealed that molecular profiling clustered bladder cancer based
on histopathogenesis and biological criteria. Moreover, gene
profiling identified novel biomarkers of the disease that were
proven to be associated with clinical and histopathological
variables when validated on tumour specimens using tissue
microarrays at the protein level, using well-characterised
antibodies and immunohistochemistry (Sanchez-Carbayo et al,
2002).
BLADDER CANCER STUDIES USING CLINICAL
SPECIMENS
Microarray analyses have been used to correlate changes in the
expression of specific genes and groups of genes within distinct
bladder tumours. Following the biological validation of these
expression–phenotype correlations, the result will be a more
complete list of the genes controlling cancer development and
progression. Gene expression profiling of bladder cancer tissues
have identified signature genes that robustly distinguish bladder
cancer subclasses. Such signature genes would ideally provide a
molecular basis for classification, yielding insight into the
molecular events underlying different clinical bladder cancer
phenotypes.
There have been few studies dealing with molecular classifica-
tion of bladder cancer expression profiling using DNA micro-
arrays. The first report monitored the expression patterns of
superficial and invasive tumour cell suspensions prepared from 36
normal and 29 bladder tumour biopsies using oligonucleotide
microarrays. This study also analysed pools of cells made from
normal urothelium, as well as pools of tumours of different stages,
such as from pTA grade I and II and pT2 grade III and IV bladder
cancer specimens (Thykjaer et al, 2001). Hierarchical clustering of
gene expression levels grouped bladder cancer specimens based on
tumour stage and grade. By organising genes with similar
expression patterns into clusters, several functionally related genes
were identified. By examining log-fold changes of expression, the
most significant genes included those involved in cell cycle, cell
growth, immunology, cell adhesion, transcription, and protein
metabolism. Superficial papillary tumours showed increased
transcription factor and ribosomal levels, as well as proteinase
encoding genes upregulation. In the invasive tumours, increased
levels of cell cycle, growth factor networks related and oncogene
transcripts were observed. A loss of cellular adhesion genes was
found in invasive tumours, which may in turn be related to
invasion and metastasis. The invading tumour cells seem to
challenge the immune system, as reflected by an increase in
immunology-related proteins (Thykjaer et al, 2001).
The combination of separate expression profiling studies of
bladder tumours and bladder cancer cell lines has allowed the
identification of the tumour-suppressor role of KiSS-1 in bladder
cancer progression (Sanchez-Carbayo et al, 2003a,b). Lower
transcript levels of KiSS-1 were observed in bladder carcinomas,
as compared to superficial tumours, and these ratios provided
prognostic information. Lower expression of this gene was also
observed in cells derived from advanced bladder tumours
(Sanchez-Carbayo et al, 2002). The analysis of the expression
patterns of KiSS-1 by in situ hybridisation on tissue microarrays
confirmed the loss of KiSS-1 in the progression of the disease, and
was associated with tumour stage, grade, and overall survival. In
this example, gene expression profiling identified a novel target
involved in bladder cancer progression with clinical relevance
(Sanchez-Carbayo et al, 2003a,b).
The most extensive expression profiling study of bladder
tumours reported to date has dealt with the development of a
predictive classifier of Ta, T1, and T2þ bladder carcinoma
subclasses. The use of a support vector machine algorithm allowed
prediction of these tumour subclasses with 75% accuracy, in an
independent set of patients. This report revealed the diagnostic
and prognostic potential of bladder tumour profiling using cross-
validation strategies to evaluate the clinical impact of the classifier
defined using independent series of tumours. Smad6 and cyclin G2
were also identified as Ta/T1 classifier genes, and their immunos-
taining patterns were validated on tissue microarrays by im-
munohistochemistry (Dyrskjot et al, 2003). This report classified
bladder tumours based on current histopathological schemes,
representing the first attempt to predict recurrence within 2 years
for patients with bladder cancer.
A recent study has compared the expression profiles of early-
stage and advanced bladder tumours using cDNA microarrays.
Gene profiling successfully classified bladder tumours based on
their progression and clinical outcome. The application of
bootstrapping techniques to hierarchical clustering and multi-
dimensional analyses segregated early-stage and invasive transi-
tional carcinomas, and identified early-stage tumours showing
gene profiles similar to invasive disease. More importantly, it
separated carcinoma in situ from papillary superficial lesions and
subgroups within early-stage and invasive tumours displaying
different overall survival. Molecular biomarkers of potential
clinical significance and critical molecular targets associated with
bladder cancer progression were identified using different
techniques, including standard t-test, single-gene logistic regres-
sion, and support vector machine algorithms. For example,
p33ING1 was found to be significantly associated with pathological
stage, tumour grade, and overall survival, when validated by
immunohistochemistry using tissue microarrays. Analysis of the
annotation of the most significant genes revealed the relevance of
critical genes and pathways during bladder cancer progression
(Sanchez-Carbayo et al, 2003b).
The application of tissue microarrays represents a high-
throughput approach for validation of potential novel markers
for bladder cancer by immunohistochemistry or in situ hybridisa-
tion in paraffin blocks (Kononen et al, 1998; Schraml et al, 1999;
Richter et al, 2000; Nocito et al, 2001). Several reports describe the
rapid evaluation of targets of interest, such as cytoskeletal actin-
associated gelsolin or E-cadherin (Rao et al, 2002), Na,K-ATPase
or cell-cycle-related markers (Espineda et al, 2003). The most
extensive tissue microarray in bladder cancer, analysing over 2000
bladder carcinomas, revealed the prognostic utility of cyclin E
(Richter et al, 2000). Focus is intensified within this field to
automate the construction of tissue microarrays. This high-
throughput approach allows further characterisation of novel
genes by in situ hybridisation of ESTs and known genes, when
specific antibodies are not available to study their potential clinical
relevance.
MOLECULAR STUDIES USING MICROARRAY
PLATFORMS FOR TARGET DISCOVERY
In addition to transcriptome expression microarrays, specific
oligonucleotide microarrays have been applied to the study of
DNA variation in clinical material. Multiple probes of short length
that differ in sequence at a single base have been designed to
identify simple polymorphisms and allelic variations in DNA. The
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automated high-throughput identification of mutations in critical
genes such as TP53, a valuable predictor for bladder cancer
outcome (Lu et al, 2002), and in the genotyping of single-
nucleotide polymorphisms (SNPs) (Primdahl et al, 2002). Not only
SNP arrays confirm known areas of chromosomal losses, they may
also have identified areas with common allelic imbalances that
could harbour potential tumour suppressors involved in bladder
cancer progression (Primdahl et al, 2002). Although initial chips
were restricted to the polymorphic areas contained in the arrays, in
the future, it should be possible to fabricate high-density SNP
microarrays for other predefined chromosomal locations or larger
regions, which could make unknown areas informative.
The application of high-throughput CGH arrays will confirm the
alterations found at the genomic level in a comprehensive detailed
manner (Pinkel et al, 1998). Microarrays can be used to define
gene copy number changes based on cohybridisation of labelled
experimental and normal DNA to an array of genomic DNA. This
technique is well suited to high-throughput whole genome
detection of chromosomal gains and losses at high resolution,
enabling rapid detection of homozygous loss, which allow
molecular phenotyping of tumours based on the underlying
abnormalities and the detection of amplicons, which may be
associated with overexpression of oncogenes. This provides a
significant advantage over laborious pregenome mapping and
transcript identification strategies. An additional advantage of this
approach is that probes may be generated using paraffin-
embedded material, greatly expanding the available specimens
for analysis. This feature can allow study of genetic changes in
tumour progression (Veltman et al, 2003).
It should be noted that microarrays technology is a convenient
platform for assays involving biomolecules other than nucleic
acids. Arrays of tissues, peptides, antibodies, proteins, and even
cells have been developed (MacBeath and Schreiber, 2000; Haab
et al, 2001; Reineke et al, 2001; Ziauddin and Sabatini, 2001). This
is further evidence of the strength and versatility for high
throughput screening. Protein microarrays provide means of
rapidly validating the genes identified by expression profiling
using DNA microarrays, at the protein level.
DISCUSSION
The majority of the studies reported to date have utilised the DNA
microarray platform using both oligonucleotide and cDNA
formats. On one side, the commercial oligonucleotide arrays,
mainly those manufactured by Affymetrix, have been used in most
of the studies using clinical material. The Rosetta oligonucleotide
arrays, well known through the predictive studies performed in
breast tumours (van ’t Veer et al, 2002), have not been utilised in
bladder cancer yet. On the other side, the homemade cDNA
microarrays have been utilised in most of the in vitro studies
reported in bladder cancer. Further studies are required using
different formats and platforms to consolidate the clinical
relevance of the findings recently reported. The majority of the
studies using clinical material have utilised standard commercial
hybridisation protocols (Thykjaer et al, 2001; Dyrskjot et al, 2003),
although the potential of linear amplification hybridisation
protocol has also been described (Sanchez-Carbayo et al,
2003a,b). Many data analysis tools have been described for target
identification. They vary from t-test algorithms or standard
hierarchical clustering (Thykjaer et al, 2001) to single logistic
regression analysis, to take into account the dispersion of the data
when comparing also two categories, or the application of
bootstrapping techniques to evaluate the robustness of hierarchical
clustering (Sanchez-Carbayo et al, 2003b). Bipartition of the data
into training and validation sets and the use of supervised vector
machine algorithms with or without factor analysis have been
utilised for subtype classification (Sanchez-Carbayo et al, 2003b)
and predictive purposes (Dyrskjot et al, 2003).
As compared to other solid tumours, there are few reports using
DNA microarrays. The use of the technology using in vitro models
is limited and warrants further studies in each of the objectives
presented here as gene and pathway discovery, functional
classification of genes, and tumour subclassification. The first
two objectives represent an open field depending on the research
area of laboratories focusing on bladder cancer. Many targets have
been identified to be involved in bladder cancer progression, and
comprehensive study of the mechanisms by which these molecules
are involved in bladder tumorigenesis or progression might
contribute to novel therapies or diagnostic tools for bladder
cancer. Interestingly, no in vivo study focused on bladder cancer
using DNA microarrays has been reported to date. Most of the
bladder cancer cell lines commercially available have been studied
with the aim of identification of genes related to histopathological
subtypes (Sanchez-Carbayo et al, 2002). However, further studies
are warranted, with new cell lines and other DNA platforms.
Bladder cancer studies using clinical material are also relatively
limited by two studies using the oligonucleotide format (Thykjaer
et al, 2001; Dyrskjot et al, 2003), and another study using cDNA
microarrays (Sanchez-Carbayo et al, 2003b). These reports have
focused mainly on tumour classification, finding satisfactory
results to segregate superficial and invasive tumours using pools
of samples representing different stages (Thykjaer et al, 2001), or
individual tumours (Dyrskjot et al, 2003; Sanchez-Carbayo et al,
2003a,b). The first attempts to apply DNA microarrays for
prediction of recurrence (Dyrskjot et al, 2003) and survival
(Dyrskjot et al, 2003; Sanchez-Carbayo et al, 2003b) have recently
been reported. Many clinical questions remain to be evaluated by
the application of DNA microarrays in classification, prediction of
overall survival, recurrence, progression, or chemosensitivity to
the current intravesical treatment in superficial disease or to the
chemotherapy utilised in invasive and metastatic disease. It is
expected that the more narrowed the clinical question to answer,
the higher the number of well-annotated cases necessary for these
analyses.
FINAL COMMENTS AND REMARKS
Expression profiling using microarrays, as stated above, is not only
changing both scientific and clinical paradigms, but is also
advancing at a rapid pace. Technical advances and improvements
are being made at each step of the microarray assembling line and
analytical process. For example, the lower cost and wider variety of
commercial arrays options, improvements in the speed and
reliability, technologies of the spotting robots, improvements in
probe labelling and hybridisation techniques, and changes in
target design are just a few to mention. In a short period of time,
DNA microarrays have moved from being a technology restricted
to a few well-funded or technically sophisticated laboratories, to
one that is widely used and will be incorporated into clinical
laboratories. This trend will continue as the quality and ease of use
of the technology increase and the costs decrease.
The studies summarised here and others indicate that expres-
sion profiling of a relatively small number of genes may provide a
molecular means of identifying clinically important tumour
subtypes and molecular targets not identified using standard
methods. Moreover, these subtypes and targets may define
subgroups of patients that will benefit from individualised
treatment regimes. It is clear that the results of these studies will
add to our understanding of the mechanisms of carcinogenesis and
may also improve our ability to diagnose and treat bladder cancer.
As interest in microarrays and their use in the study of cancer
continue to increase, so does the likelihood that their use will have
critical clinical applications.
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have already had a tremendous impact on bladder cancer research,
major challenges remain. Microarray data can clearly improve
tumour classification and provide empirical clinical correlations.
However, the patterns and profiles observed may still be
remarkably cryptic to answer specific clinical issues. Carefully
controlled, large-scale expression profiling studies on large
numbers of clinically well-annotated cases are needed before the
final clinical utility of this technique can be accurately judged
(Figure 2).
Biologically straightforward results are emerging. Being able to
link these data to oncogenic pathways, underlying mutational
events, and genomic signals remains an important goal. This
process must be reached in order to maximise insights into the
underlying biology of cancer, which will ultimately prove to be of
therapeutic relevance. Further approaches are required to combine
data from tumour expression profiling with that obtained from
model systems and genomic analyses, in order to link the
complementary aspects of cancer biology.
Knowledge of the expression patterns of primary cancer cells,
normal and malignant tissues is providing insights into the biology
of bladder cancer. Global views of the malignant transcriptome
and genome are proving to be valuable for understanding
neoplastic transformation, cancer diagnosis, prediction of clinical
outcome, and response to therapeutic intervention. Gene expres-
sion profiling could define, at the molecular level, the clinical and
histopathological phenotypes of tumours. Moreover, the tumour
subclasses are likely to reflect the basic differences in the cell
biology of the tumours. Gene expression monitoring by DNA
microarrays is becoming a novel tool for identifying new
cancer classes (class discovery) or for assigning tumours to known
classes (class prediction). Reports using different microarray
platforms and analysing specific cancer subgroups are finding
consensus on subclasses and signatures of the disease with
predictive utility.
Overall, the use of microarray technologies for the study of
bladder cancer remains a new research field. The results reported
so far represent preliminary data that need to be contrasted by
different groups using different series of patients. Creation of
international tumour banks represents an option that might
facilitate interactive research among different laboratories. Further
efforts using in vitro and in vivo models are warranted to
functionally characterise the pathways by which many of the
targets are already identified to be involved in tumorigenesis or
bladder cancer progression. The utility of the application of
microarrays has not yet estimated many clinical issues. Identifica-
tion of Ta-T1-IS subtypes within the superficial disease and
patients more likely to develop positive lymph nodes or distant
metastases are critical subclassification questions to be answered.
An area that will provide critical targets for clinical intervention
is that of pharmacogenomics. Studies evaluating biological
markers (at the DNA, RNA or protein level) to predict the drug
efficacy or the relative risk of adverse effects in individual patients
are still needed for many tumour types. In the near future, gene
profiling will provide an effective means of predicting the response
against specific therapeutic regimes based on the molecular
signatures of the tumours associated with their chemosensitivity
or resistance to anticancer drugs. Moreover, the discovery of
molecular pathways altered in cancer progression, as well as the
identification of molecule-susceptible targets, would lead to the
development of novel alternative therapies. The combined
information revealed by these studies allows also identification
of new molecular determinants involved in the progression of the
disease with clinical diagnostic or predictive utility. The classical
tumour marker concept of an individual biological determinant
will be substituted by the use of cluster of genes as predictive
classifiers. These genetic signatures will allow a better chance of
cure by opting for the most appropriate treatment, while
maintaining the quality of life.
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